ATUM Announces Leap-In Transposase Licensing Agreement with Codiak Biosciences to Support Manufacturing

ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In Transposase technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines.

Under the terms of the agreement, ATUM will provide Codiak access to its Leap-In Transposase technology to generate mammalian cells expressing exosomes engineered to deliver therapeutic payloads. The Leap-In technology is an integrated solution combining proprietary re-coding algorithms, unique genetic vector elements as well as a transposon-based mechanism for efficient insertion of genetically stable elements into the genome.

Scott Estes, Ph.D., VP of Cell Line Development at Codiak, said, "Through years of rigorous research and clinical validation we have created a platform for engineering and manufacturing therapeutic exosomes with various payloads on the surface or inside the lumen. We believe ATUM's transposase technology has the potential to effectively synergize with Codiak's engEx Platform to further enhance loading these vesicles, making them more potent and reducing cost of goods."